- Stock: ZGNX (NASDAQ)
- Headquarters: Emeryville, CA
- CEO: Stephen J. Farr
- Founded: 2006
- zogenix.com
Zogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome. ZX008 has received orphan drug designation in the United States and European Union (EU), for the treatment of Dravet syndrome. The Company has an additional product candidate, Relday (risperidone once-monthly long-acting injectable) for the treatment of schizophrenia. Relday is a long-acting injectable formulation of risperidone. Risperidone is used to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers 13 years of age and older. It has completed the Phase I program for Relday.
Key stats and ratios
| Q2 (Jun '17) | 2016 | |
| Net profit margin | -315.13% | -238.08% |
| Operating margin | -309.84% | -251.94% |
| EBITD margin | - | -217.86% |
| Return on average assets | -45.10% | -25.57% |
| Return on average equity | -99.73% | -45.26% |
| Employees | 67 |
No comments:
Post a Comment